283 related articles for article (PubMed ID: 35004284)
1. Oncolytic Viruses and Cancer, Do You Know the Main Mechanism?
Kooti W; Esmaeili Gouvarchin Ghaleh H; Farzanehpour M; Dorostkar R; Jalali Kondori B; Bolandian M
Front Oncol; 2021; 11():761015. PubMed ID: 35004284
[TBL] [Abstract][Full Text] [Related]
2. Perspectives on immunotherapy via oncolytic viruses.
Reale A; Vitiello A; Conciatori V; Parolin C; Calistri A; Palù G
Infect Agent Cancer; 2019; 14():5. PubMed ID: 30792754
[TBL] [Abstract][Full Text] [Related]
3. Updates to the antitumor mechanism of oncolytic virus.
Bai Y; Hui P; Du X; Su X
Thorac Cancer; 2019 May; 10(5):1031-1035. PubMed ID: 30900824
[TBL] [Abstract][Full Text] [Related]
4. A review exploring the fusion of oncolytic viruses and cancer immunotherapy: An innovative strategy in the realm of cancer treatment.
Chattopadhyay S; Hazra R; Mallick A; Gayen S; Roy S
Biochim Biophys Acta Rev Cancer; 2024 May; 1879(4):189110. PubMed ID: 38754793
[TBL] [Abstract][Full Text] [Related]
5. Arming oncolytic viruses to leverage antitumor immunity.
de Gruijl TD; Janssen AB; van Beusechem VW
Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
[TBL] [Abstract][Full Text] [Related]
6. Design and application of oncolytic viruses for cancer immunotherapy.
Ylösmäki E; Cerullo V
Curr Opin Biotechnol; 2020 Oct; 65():25-36. PubMed ID: 31874424
[TBL] [Abstract][Full Text] [Related]
7. From Benchtop to Bedside: A Review of Oncolytic Virotherapy.
Choi AH; O'Leary MP; Fong Y; Chen NG
Biomedicines; 2016 Aug; 4(3):. PubMed ID: 28536385
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic viruses and their application to cancer immunotherapy.
Chiocca EA; Rabkin SD
Cancer Immunol Res; 2014 Apr; 2(4):295-300. PubMed ID: 24764576
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic Immunotherapy: Can't Start a Fire Without a Spark.
Muscolini M; Tassone E; Hiscott J
Cytokine Growth Factor Rev; 2020 Dec; 56():94-101. PubMed ID: 32826166
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in targeting cancer stem cells using oncolytic viruses.
Zhang YN; Wang SB; Song SS; Hu PY; Zhou YC; Mou YP; Mou XZ
Biotechnol Lett; 2020 Jun; 42(6):865-874. PubMed ID: 32166558
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in oncolytic virus-based cancer therapy.
Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements.
Jin KT; Du WL; Liu YY; Lan HR; Si JX; Mou XZ
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33546172
[TBL] [Abstract][Full Text] [Related]
13. Review: Oncolytic virotherapy, updates and future directions.
Fountzilas C; Patel S; Mahalingam D
Oncotarget; 2017 Nov; 8(60):102617-102639. PubMed ID: 29254276
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses.
Guo ZS; Thorne SH; Bartlett DL
Biochim Biophys Acta; 2008 Apr; 1785(2):217-31. PubMed ID: 18328829
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy.
Zhang Y; Li Y; Chen K; Qian L; Wang P
Cancer Cell Int; 2021 May; 21(1):262. PubMed ID: 33985527
[TBL] [Abstract][Full Text] [Related]
16. The two-faces of NK cells in oncolytic virotherapy.
Marotel M; Hasim MS; Hagerman A; Ardolino M
Cytokine Growth Factor Rev; 2020 Dec; 56():59-68. PubMed ID: 32586674
[TBL] [Abstract][Full Text] [Related]
17. Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines.
Holay N; Kim Y; Lee P; Gujar S
Front Immunol; 2017; 8():800. PubMed ID: 28751892
[TBL] [Abstract][Full Text] [Related]
18. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
19. Genetic modification of oncolytic viruses to enhance antitumor immunity.
Davola ME; Vito A; Wei J; El-Sayes N; Workenhe S; Mossman KL
Methods Enzymol; 2020; 635():231-250. PubMed ID: 32122548
[TBL] [Abstract][Full Text] [Related]
20. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them.
Hu PY; Fan XM; Zhang YN; Wang SB; Wan WJ; Pan HY; Mou XZ
Appl Microbiol Biotechnol; 2020 Oct; 104(19):8231-8242. PubMed ID: 32816087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]